The FDA approved a new 300 mg/2 mL dose of Celltrion’s omalizumab biosimilar, Omlyclo, for the treatment of four allergic and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback